表皮生长因子受体突变型肺癌的治疗方法

Title:Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer

Volume: 18 Issue: 8

关键词: 肺癌，表皮生长因子受体蛋白-酪氨酸激酶，单克隆抗体，泛素，热休克蛋白，组蛋白去乙酰化酶。

摘要: Lung cancer surfaces to be the predominant determinant of mortality worldwide constituting 13% and 19% of all new cancer cases and deaths related to cancer respectively. Molecular profiling has now become a regular trend in lung cancer to identify the driver mutations. Epidermal Growth Factor Receptor (EGFR) is the most regular driver mutation encountered in Non-Small Cell Lung Cancer (NSCLC). Targeted therapies are now available for the treatment of EGFR mutant NSCLC. EGFR mutation is more frequently expressed in adenocarcinoma than squamous cell carcinoma. This article presents a detailed molecular insight of the therapeutic approaches for the treatment of EGFR mutant lung cancer. The article delineates molecular mechanism of the drugs that are approved, the drugs that are in clinical trial and the drugs that have not entered a clinical trial but shows promising future in the treatment of EGFR mutant lung cancer. Furthermore, this article provides concise information on relevant combinational or monotherapy clinical trials that have been completed for various approaches.

Cite this article as:

Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer, Current Cancer Drug Targets 2018; 18 (8) . https://dx.doi.org/10.2174/1568009617666170623123848